Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says

Pfizer and its partner BioNTech said Monday that they would file for authorization of their Covid-19 vaccine for use in children after clinical trial results showed encouraging antibody levels in volunteers and side effects similar to those in teens and young adults. The pediatric study, in children ages 5 to 11, is the first to disclose results in young children. It used a lower dose of the vaccine than the one currently being administered, because earlier studies showed that the adult dose could cause more side effects. Adults receive two 30 microgram doses of the vaccine three weeks apart. In school-aged children, this was lowered to 10 micrograms.